{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:55:41Z","timestamp":1740167741483,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136"],"award-info":[{"award-number":["NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136","NU22-03-00136"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health of the Czech Republic \u2013 Conceptual Development of Research Organization"},{"name":"National budget through MAYS, LRI CZECRIN"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-024-02215-9","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:02:14Z","timestamp":1710288134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-8148","authenticated-orcid":false,"given":"Daniela","family":"\u017d\u00e1\u010dkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luk\u00e1\u0161","family":"Semer\u00e1d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Klamov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luk\u00e1\u0161","family":"Stejskal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"B\u011blohl\u00e1vkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Karas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Cmunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"\u010cern\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159ina","family":"Proch\u00e1zkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"\u010ci\u010d\u00e1tkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ane\u017eka","family":"Kvetkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-3372","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Hor\u0148\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Skoumalov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Srbov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-3247","authenticated-orcid":false,"given":"Cyril","family":"\u0160\u00e1lek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Buffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslava","family":"Voglov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Jur\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Folta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Je\u017e\u00ed\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"\u017di\u017ekov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate\u0159ina","family":"Machov\u00e1 Pol\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Papaj\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"\u017d\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-7069","authenticated-orcid":false,"given":"Pavel","family":"Jindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Svobodn\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radka","family":"\u0160t\u011bp\u00e1nov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-9887","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"2215_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2215_CR2","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","volume":"34","author":"G Sharf","year":"2020","unstructured":"Sharf G, Marin C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34:2102\u201312.","journal-title":"Leukemia"},{"key":"2215_CR3","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.3747\/co.21.1736","volume":"21","author":"D Sanford","year":"2014","unstructured":"Sanford D, Kyle R, Lazo-Langner A, Xenocostas A, Chin-Yee I, Howson-Jan K, et al. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Oncol. 2014;21:e241\u20139.","journal-title":"Curr Oncol"},{"key":"2215_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.leukres.2015.07.004","volume":"39","author":"M Breccia","year":"2015","unstructured":"Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res. 2015;39:1055\u20139.","journal-title":"Leuk Res"},{"key":"2215_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00432-016-2159-7","volume":"142","author":"Q Jiang","year":"2016","unstructured":"Jiang Q, Liu ZC, Zhang SX, Gale RP. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2016;142:1539\u201347.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2215_CR6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2147\/PPA.S163393","volume":"12","author":"J Lou","year":"2018","unstructured":"Lou J, Huang J, Wang Z, Wen B, Tu C, Huang W, et al. Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey. Patient Prefer Adherence. 2018;12:1025\u201332.","journal-title":"Patient Prefer Adherence"},{"key":"2215_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/10428194.2017.1337114","volume":"59","author":"LA Villemagne Sanchez","year":"2018","unstructured":"Villemagne Sanchez LA, O\u2019Callaghan C, Gough K, Hall K, Kashima Y, Seymour JF, et al. Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leuk Lymphoma. 2018;59:406\u201315.","journal-title":"Leuk Lymphoma"},{"key":"2215_CR8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1634\/theoncologist.2018-0831","volume":"24","author":"KE Flynn","year":"2019","unstructured":"Flynn KE, Myers JM, D\u2019Souza A, Schiffer CA, Thompson JE, Atallah E. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Oncologist. 2019;24:1253\u20138.","journal-title":"Oncologist"},{"key":"2215_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/10428194.2020.1839655","volume":"62","author":"VNMF Tromp","year":"2021","unstructured":"Tromp VNMF, Timmers L, Koningen L, Janssen JJWM, Westerweel PE, Geelen IGP, et al. Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views. Leuk Lymphoma. 2021;62:649\u201358.","journal-title":"Leuk Lymphoma"},{"key":"2215_CR10","doi-asserted-by":"publisher","first-page":"17239","DOI":"10.1002\/cam4.6296","volume":"12","author":"Y Chen","year":"2023","unstructured":"Chen Y, Xu N, Yang Y, Liu Z, Xue M, Meng L, et al. Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia. Cancer Med. 2023;12:17239\u201352.","journal-title":"Cancer Med"},{"key":"2215_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.clml.2018.04.005","volume":"18","author":"G Saglio","year":"2018","unstructured":"Saglio G, Sharf G, Almeida A, Bogdanovic A, Bombaci F, \u010cugurovi\u0107 J, et al. Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective. Clin Lymphoma Myeloma Leuk. 2018;18:375\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2215_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"2215_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.16083","volume":"187","author":"MG Berger","year":"2019","unstructured":"Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol. 2019;187:337\u201346.","journal-title":"Br J Haematol"},{"key":"2215_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11899-019-00524-w","volume":"14","author":"M Copland","year":"2019","unstructured":"Copland M. Is There a Role for Dose Modification of TKI Therapy in CML? Curr Hematol Malig Rep. 2019;14:337\u201345.","journal-title":"Curr Hematol Malig Rep"},{"key":"2215_CR15","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375\u201383.","journal-title":"Lancet Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02215-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T18:42:13Z","timestamp":1713897733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02215-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":15,"alternative-id":["2215"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02215-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"30 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D\u017d served as a member of advisory board for Novartis, served on a speaker\u2019s bureau for Novartis, Pfizer and Angelini, served as a consultant for Novartis and Angelini, and received travel grants from Novartis, Pfizer, Angelini and Astra Zeneca. LSe received travel grant from Novartis and Angelini. EF served as a member of advisory board for Novartis and Zentiva, served on a speaker\u2019s bureau for Novartis, Zentiva, and Angelini, participated in an expert opinion panel for Pearls Health Cyber, and received travel support from ELN Foundation and Altium International. P\u010c served as a consultant for Novartis and received travel support from Novartis and Angelini. TH served on a speaker\u2019s bureau for Novartis, served as a consultant for Angelini, and received travel grant from Novartis. PJ served as a member of advisory board for Novartis, Astra Zeneca, Takeda, and Bristol-Myers Squibb, and received travel grants from Novartis, Astra Zeneca, and MSD. JM received research support from Novartis, Bristol-Myers Squibb, and Pfizer. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The HALF study was approved by the Multicentric Ethical Committee. The Anti-HALF questionnaire was approved by the Ethical Committees of all participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided informed written consent with participation in the HALF trial or in the Anti-HALF questionnaire project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}